Barclays’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Barclays’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13,000	Closed	-$2.03M	–	5702
2020 Q2	$2.03M	Hold	13,000	–	–	﹤0.01%	2115
2020 Q1	$1.88M	Buy	+13,000	New	+$2.51M	﹤0.01%	2353
2019 Q4	–	Sell	-15,000	Closed	-$1.2M	–	6953
2019 Q3	$1.2M	Hold	15,000	–	–	﹤0.01%	3483
2019 Q2	$1.42M	Buy	+15,000	New	+$1.3M	﹤0.01%	3312

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's RETA Position: Q3 2023 in Review

Barclays sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 79,034 shares — an estimated $8.06M sold.

Barclays first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $8.06M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Barclays reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Barclays sold 79,034 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $8.06M.
Barclays first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
Barclays's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $8.06M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.